these patients. Fifteen patients with chordomas had previously undergone surgical treatment at another institution. Conventional external beam radiotherapy was previously performed in five patients with chordomas and in one patient with chondrosarcoma. Significant demographic characteristics are summarized in Table 1 . There was a female predominance among patients with both tumors (average female/male ratio of 1.21:1 for those with chordoma; 1.5:1 for those with chondrosarcoma). The mean age of these patients was 40.7 years (range 8-73 years). The clinical manifestations present at the onset of the disease are summarized in Table 2 . The most common signs and symptoms were neuroophthalmological (decrease in vision, blurred vision, and oculomotor nerve palsies), which were observed in 39 patients (61.9%), and headache, which was observed in 11 patients (17.5%). Sixth cranial nerve palsy was the most frequently observed clinical sign (25 patients [39.7%] ). The distribution of signs and symptoms was similar in patients with typical chordomas, chondroid chordomas, and chondrosarcomas. Complete medical, neurological, neuroophthalmological, and radiological evaluations were performed in the pre-and postoperative periods. All patients underwent T 1 -and T 2 -weighted and gadolinium-enhanced MR imaging and bone-window computerized tomography studies to determine bone involvement (Table 3) . Immediate postoperative imaging studies were performed within 48 hours of operation. Preoperative and immediate postoperative neuroradiological examinations were performed in our hospitals. Fifty-seven patients (90.5%) attended follow up for at least 1 month at our institutions after discharge from the hospital. The patients were followed at intervals of headache  9  2  11  diplopia  2  2  decreased vision  6  1  7  blurred vision  1  1  cranial nerve palsy  first  2  2  third  1  1  fourth  2  2  sixth  22  3  25  hemiparesis  2  1  3  neck pain  4  4  extremity numbness  3  3  facial pain or difficulty  swallowing  2  2  nasopharynx mass  2  1  3  nausea/vomiting  1  1  other*  1  1  2 * These signs and symptoms included transient memory loss, ear pain, dizziness, facial numbness, neck mass, gait disturbance, hearing loss, pain in the oropharynx, pathological laughing and crying in one patient with chordoma, and seizure or dysphasia, retroauricular mass, and tooth pain in one patient with chondrosarcoma. + middle fossa  1  1  PF  1  1  PF + retropharyngeal + occipital condyle  1  1  PA  2  2  PA + CS  1  1  PA + CS + suprasellar  1  1  temporomandibular joint + IT  1  1  C1-3  6  6 approximately 6 months. Forty-one patients (65.1%) were followed in our hospitals, and 22 (34.9%) were followed and examined by distant physicians (with the results being reported to our institutions). In 30 patients (47.6%) follow-up studies were performed in our hospitals and in the remaining patients the studies were performed at several different institutions; in the latter patients neuroimaging studies were forwarded to us and were analyzed by the surgeon and by a neuroradiologist in our hospitals.
Management of Disease
Surgical Treatment. Fifteen patients with chordoma and one with chondrosarcoma had undergone 41 and two previous operations elsewhere, respectively. Ninety-five surgical procedures (83 in 53 patients with chordomas and 12 in 10 patients with chondrosarcomas) were performed at our institutions. The first procedure undertaken in the 63 patients was performed via the following approaches: cranioorbitozygomatic/extended cranioorbitozygomatic (26 cases), unilateral/bilateral maxillotomy (12 cases), transsphenoidal/extended transsphenoidal (10 cases), transcondylar (four cases), transoral (three cases), anterior cervical decompression and fusion (three cases), suboccipital craniotomy (two cases), retromastoid-petrosal (two cases), and frontotemporal craniotomy (one case). Combining the number of previous surgeries and those performed in our institutions there were 136 procedures (2.3 per patient): 29 patients underwent one procedure, 17 underwent two procedures, six underwent three procedures, and 11 underwent four or more procedures. The surgical procedure included removal of soft tumor tissue and extensive drilling of bone in all patients. The extent of resection was evaluated using MR imaging performed during the immediate postoperative period (within 48 hours of operation), and 6 months later. The extent of resection was determined by a neuroradiologist and classified as follows: radical (absence of residual tumor or presence of a small questionable area); subtotal (Ͼ 90% resection); and partial (Ͻ 90% resection). A two-stage operation was indicated in patients whose tumors extended into the anatomical areas preoperatively deemed inaccessible via only one approach; a two-stage procedure was also indicated depending on the size of residual tumor after the first operation. When we could not obtain data on the first operation performed elsewhere, we considered the operation undertaken at our institutions to be the "first." Radiation Therapy. Radiotherapy was performed in 36 patients with chordomas (12 underwent proton-beam radiotherapy; 13, proton-photon therapy; and 10, conventional radiation therapy) and in one patient with chondrosarcoma. In most cases radiation therapy was conducted out of our institutions, and data on the doses of proton radiation were available in 12 patients (mean 70.53 CGE median 72 CGE, SD 5.235 CGE, and range 60-77.4 CGE); data on the doses of conventional radiation were available in only three patients (mean 51.77 Gy, median 55 Gy, SD 5.862 Gy, and range 45-55.3 Gy). Surgery alone was performed in 18 patients with chordomas and in nine patients with chondrosarcomas in our institutions, although five among the former and one among the latter groups had previously undergone conventional radiation therapy.
Functional Outcome. To assess preoperative, immediate postoperative (within 48 hours of surgery), and followup functional outcome, the KPS was used to measure the degree of disability. Patients were classified into one of three groups: 1) normal function or minimal symptoms and ability to work (KPS score 80-100); 2) independent but not able to work (KPS score Յ 70); and 3) moderate or severe disability (KPS score Յ 50). For patients who experienced tumor recurrence and consequent clinical deterioration, the best KPS score obtained during the followup course was used. For patients who died during the immediate postoperative course, the KPS score acquired before death was used to indicate both the immediate postoperative and follow-up scores. Nine patients did not attend 6 months of follow up and did not receive a KPS score at this time (six with typical chordomas, one with chondroid chordoma, and three with chondrosarcomas). Follow-up analysis was performed using the Kaplan-Meier method to determine overall survival and RFS rates.
Histopathological Diagnosis
Diagnosis of chordoma and chondrosarcoma was made using the morphological criteria described by Heffelfinger, et al. 23 In some cases in which the diagnosis could not be convincingly established based on morphological criteria, immunohistochemical studies were conducted. The pathological findings were compatible with typical chordomas in 41 patients, chondroid chordomas in 12, and chondrosarcomas in 10. Only one lesion in a patient with typical chordoma was considered to have an aggressive behavior with some atypical characteristics. Immunohistochemical studies were performed in 24 patients and included S-100 protein, epithelial membrane antigen, and cytokeratin. The main immunohistochemical findings are summarized in Table 4 .
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Chordomas of the skull base 3 * EMA = epithelial membrane antigen; neg = negative; pos = positive.
Additional Studies
Additional studies included cytogenetic analysis, assays for estrogen and progesterone, and PCNA index.
Cytogenetic Analysis. Flow cytometric DNA analysis was performed in seven patients with chordomas. Karyotype analysis was performed in 18 patients (10 with typical chordomas, four with chondroid chordomas, and four with condrosarcomas) and results were abnormal in nine (64.3%) of 14 patients with chordomas and in one (25%) of four with chondrosarcomas.
Assays for estrogen and progesterone receptors were performed in 13 patients with chordomas. Testing for PCNA was performed in 12 patients with chordomas and in one with chondrosarcoma.
Statistical Analysis
Statistical analysis was performed using the Fisher exact test for comparing proportions and the log rank test and Kruskall-Wallis nonparametric ANOVA (with the Dunn multiple comparisons posttest) for comparison of survival curves and rates. An ␣-error probability not exceeding 5% was considered significant for two-tailed p tests. The tests were performed using the GraphPad PRISM (version 2.0; GraphPad Software Inc., San Diego, CA).
RESULTS

Surgical Treatment
Radical, subtotal, and partial resections were achieved in 31 (49.2%), 18 (28.6%), and 14 (22.2%) of all treated patients, respectively. Although the extent of resection was not assessed by volumetric measures, in no patient undergoing partial resection was only a biopsy sample obtained; in several patients extensive resection was performed but 90% resection of the tumor was not achieved. Twenty-four (45.3%), 15 (28.3%), and 14 (26.4%) of the patients with chordomas underwent radical, subtotal, and partial removal of the their tumors, and radical and subtotal resection was achieved in seven and three patients with chondrosarcomas, respectively. Nineteen patients with chordomas underwent previous surgery before being treated at our institutions. In terms of those with and without a history of surgery, radical resection was achieved in six and 15 patients (31.6% and 44.1%), subtotal resection in three patients and 15 patients (15.8% and 44.1%), and partial resection in 10 patients and four patients (52.6% and 11.8%), respectively. The differences of proportions between radical (p = 0.0022, df = 1 [Fisher exact test]) and subtotal resections (p = 0.0014, df = 1 [Fisher exact test]) achieved in patients with and without a history of surgery were significant. Surgery-related complications were observed in 38 patients (60.3%). Neurological complications were observed in 37 patients: cranial nerve palsy in 22 cases; CSF leakage in five cases; postoperative hydrocephalus in three cases; meningitis, epidural fluid collection/hematoma, pituitary insufficiency, seizures and quadriparesis in two cases each; and basal ganglia infarction, pneumocephalus, intracerebral hematoma and transient paresis of superior trunk of brachial plexus in one patient each. Eighteen patients (28.6%) sustained additional permanent postoperative neurological deficits (cranial nerve palsy, seizure, paresis of the brachial plexus, and vegetative state), and 14 experienced transient postoperative neurological deficits (cranial nerve palsy and quadriparesis). A summary of affected cranial nerves is presented in Table 5 . Of 107 preoperative cranial nerve palsies, 27 (25.2%) were improved after surgery (100%, 66.7%, 50%, and 35.7% of the patients with facial pain [fifth cranial nerve], and fourth, sixth, and seventh cranial nerve palsies, respectively). Of the 22 patients with postoperative cranial nerve deficits, nine experienced transient deficits of one or two nerves (100%, 60%, 60%, and 36.4% of the third, fifth, sixth, and seventh nerve palsies, respectively) and 13 suffered some persistent deficit of one or more nerve. Other complications observed were oronasal fistulas in two cases, and epistaxis requiring surgical hemostasis, dislodgment of a tooth, temporal muscle atrophy, nasal septum perforation, sinus mucosa inflammation, middle ear effusion, fluid collection in a thigh wound, asymptomatic mediastinal hematoma, malocclusion of the jaw, pneumonia, retropharyngeal fluid collection, nasal discharge, polyp in the soft palate, venous thrombosis/ thromboembolism, and pneumothorax in one patient each. Nineteen patients (61.3%) in whom radical removal and 13 patients (72.2%) in whom subtotal removal was achieved sustained one or more surgery-related complications (no significant difference, p = 0.5410, df = 1 [Fisher exact test]). Fifteen patients (48.4%) in whom radical removal and 12 patients (66.7%) in whom subtotal removal was achieved suffered one or more neurological complication (no significant difference p = 0.3739, df = 1 [Fisher exact test]). A comparison of the postoperative complications observed in patients who underwent radical or subtotal resection is presented in Table 6 .
Follow-Up Review
The overall clinical and/or neuroimaging follow-up period ranged from 1 to 150 months (mean 46.1, SD 40.2, median 38 months), from 1 to 150 months (mean 49.9, SD 39.5, median 40 months) in patients with chordomas and 1 to 125 months (mean 28.3, SD 38.7, median 12 months) in those with chondrosarcomas. Survival. The survival curves for patients with chordomas and chondrosarcomas are presented in Fig. 1 . The 5-year survival estimates were 85.9%, 87.8% and 100%, respectively, for patients with typical chordomas, chondroid chordomas, and chondrosarcomas. There were no significant differences among survival curves for the three types of tumor (p = 0.3805, df = 2 [Kruskal-Wallis nonparametric ANOVA]; p = 0.6800, for the three groups [log rank test]). The Dunn multiple comparisons posttest showed no significant difference between the curves for patients with chordomas and chondrosarcomas (p Ͼ 0.05) nor between those with typical chordomas and chondroid chordomas (p Ͼ 0.05).
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Recurrence-Free Survival. The graphs in Fig. 2 upper show the RFS curves for all patients, for patients with chordomas and for patients with condrosarcomas. The 1-year RFS estimates were 82.5%, 80.1%, and 100% and the 5-year RFS estimates were 54.4%, 50.7%, and 100%, respectively, for patients with all tumor types, those with chordomas, and those with chondrosarcomas. There was no significant difference among the RFS curves for three of these groups (p = 0.1141, [Kruskal-Wallis nonparametric ANOVA]). Posttest analysis (the Dunn multiple comparisons test) showed no significant difference between all tumors and chordomas (p Ͼ 0.05), but showed significant difference between the RFS curves for all tumors and chondrosarcomas (p Ͻ 0.01) and between the curves for patients with chordomas and chondrosarcomas (p Ͻ 0.001). The RFS curves, according to histopathological diagnosis, are presented in Fig. 2 lower. The RFS estimates were 83.5%, 70%, and 100% at 1 year and 52.2%, 50%, and 100% at 5 years, respectively, for patients with typical chordomas, those with chondroid chordomas, and those with chondrosarcomas. There was no significant difference among the curves for patients with typical chordomas, chondroid chordomas, and chondrosarcomas (p = 0.1114, for all three groups [Kruskal-Wallis nonparametric ANOVA test]). The Dunn multiple comparisons posttest showed no difference between the curves for patients with typical and chondroid chordomas (p Ͼ 0.05), but demonstrated significant difference between those with typical chordomas and chondrosarcomas (p Ͻ 0.01), as well as between those with chondroid chordomas and chondrosarcomas (p Ͻ 0.05). The RFS curve demonstrated in patients with chordomas who underwent previous surgery elsewhere was not significantly worse than that observed in patients not previously surgically treated (p = 0.0671, df = 1 [log rank test]). The RFS estimates were 86.1% and 74.0% at 1 year and 67.7% and 32.3% at 5 years, respectively, for patients with chordomas with and without a history of surgery. There was no difference between the RFS curves for patients with chordomas when sex was analyzed as a prognostic factor (p = 0.4240, df = 1 [log rank test]), nor when age of onset of symptoms was analyzed as a prognostic factor (p = 0.4227, for seven groups [Kruskal-Wallis nonparametric ANOVA test]). Chordomas of the skull base 5 * Complications included fluid collection in the wound (two), oronasal fistulas (two), dislodgment of a tooth (one), septum perforation (one), sinus mucous inflammation (one), nasal discharge (one), middle ear effusion (one), polyp in the soft palate (one), malocclusion of the jaw (one), venous thrombosis/thromboembolism (one), asymptomatic mediastinal hematoma (one), and pneumothorax (one). mates were 96%, 88.2%, and 53.9% at 1 year and 63.7%, 79.3%, and 15.4% at 5 years, respectively, for patients who underwent radical, subtotal, and partial resections. Significant difference was demonstrated in survival curves among patients who underwent radical, subtotal, or partial resection (p Ͻ 0.0001, three groups [Kruskal-Wallis nonparametric ANOVA test]). The Dunn multiple comparisons posttest showed no difference in survival curves for patients who underwent radical and subtotal resections (p Ͼ 0.05), but significant difference was shown in curves for patients who underwent radical and partial resections (p Ͻ 0.001) and subtotal and partial resections (p Ͻ 0.001). Figure 3 lower depicts the RFS for patients with chordoma when the extent of resection was analyzed as a prognostic factor. The RFS estimates were 94.7%, 84.9%, and 53.9% at 1 year and 59.8%, 65.9%, and 23.1% at 5 years, respectively, for patients who underwent radical, subtotal, and partial resections. Significant difference was demonstrated among the curves for patients who underwent radical, subtotal, or partial resection (p Ͻ 0.0005, three groups [Kruskal-Wallis nonparametric ANOVA test]). The Dunn multiple comparisons posttest showed no difference between the curves for patients who underwent radical and subtotal resections (p Ͼ 0.05), but significant difference was demonstrated in curves for patients who underwent radical and partial resections (p Ͻ 0.001) and subtotal and partial resections (p Ͻ 0.001).
Mortality. Nine patients with chordoma died during the follow-up period (overall mortality rate of 14.3% and mortality rate of 17% in patients with chordoma). Six patients (33.3%) who had undergone previous surgery elsewhere and three patients (8.6%) in whom no previous surgery was performed died during the follow-up period, and the difference was significant (p = 0.0480). One patient with chordoma died in the immediate postoperative period (surgery-related mortality rate of 1.6% for all patients and 1.9% for patients with chordomas). This patient had a history of radiation therapy, surgery, and occlusion of the internal carotid artery, and his physiological reserve, as measured by xenon cerebral blood flow study, was poor. He required surgery for brainstem decompression, but an episode of hypotension in the immediate postoperative period caused a massive brain infarction and death. Eight other patients died at 17, 18, 22, 33, 39, 87, 96, and 131 months, respectively, after the first surgery due to progression of the disease.
Postoperative Functional Outcome
Preoperative and postoperative functional disabilities as assessed by the KPS, are presented in Table 7 . Preoperatively eight patients (12.7%) with typical chordoma, chondroid chordoma, and chondrosarcomas had KPS scores of less than or equal to 70, and postoperatively 11 patients (17.5%) had scores of at least 70. Of the patients in whom function worsened postoperatively, three harbored typical chordomas. Assessment at 6 months postoperatively demonstrated that three additional patients with typical chordomas also experienced worsened function (KPS score Յ 70). There was no significant difference in the pre-and postoperative KPS scores (Fisher exact test, df = 1) for all patients (p = 1), those with typical chordomas (p = 1.745), chondroid chordomas (p = 1.5217), and chondrosarcomas (p = 1.4180).
Radiation Therapy
The RFS estimates for patients with chordomas were 90.9%, 19.4%, 38.5%, and 0% at 4 years, respectively, for those who underwent proton-beam radiotherapy, conventional radiation therapy, no radiation therapy, and previously radiation therapy (Fig. 4) . There was no significant difference among the curves (p = 0.0537, four groups [Kruskal-Wallis non parametric ANOVA]). The Dunn multiple comparisons posttest showed significant difference between the curves for patients who underwent proton-beam and those who underwent conventional radiation therapy (p Ͻ 0.05) but no significant differences for all other combinations of groups (p Ͼ 0.05 for all combinations). Major complications occurred after proton-beam radiotherapy (total dose of 72 CGE per patient) in three patients with chordomas and in one with chondrosarcoma. These patients later presented with clinical and radiological signs of radiation-induced necrosis. In the first patient, signs suggesting necrosis in the mesial aspect of the temporal lobe were noted in conjunction with seizures (follow-up duration of 12 months), hearing loss, and radiation-induced osteonecrosis of the temporal bone (histopathologically confirmed) with consequent cholesteatoma (follow-up duration of 48 months). In the second patient, signs suggestive of radiation-induced damage of the brainstem and clinical and radiological signs of tumor recurrence were demonstrated (follow-up duration 24 months). In the third patient, MR studies obtained at the 12-month follow-up examination revealed several spotted areas at the brainstem and a well-defined area suggestive of radiation-induced necrosis in the temporal lobe. The fourth patient presented with chronic mastoiditis following the dicovery of histologically confirmed radiation-induced
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Chordomas of the skull base 7 * C = chondrosarcoma; CC = chondroid chordoma; T = total; TC = typical chordoma. † For patients with tumor recurrence, the best KPS score obtained during the follow-up period was used. For those who died during the immediate postoperative period, the KPS score obtained before death was used for both the immediate immediate postoperative and follow-up score. Nine patients did not reach 6 months of follow up, and they did not receive scores at this time (six with typical chordomas, one with condroid chordoma, and three with condrosarcomas). Assays for estrogen and progesterone receptors performed in 13 patients with chordoma were positive for estrogen receptors in one patient (7.7%) and for progesterone receptors in another patient (7.7%). The PCNA assay performed in 12 patients with chordomas and in one with chondrosarcoma showed an increased index (Ͼ 10%) in five patients (41.7%) with chordomas. There was no difference in the proportions of recurrence or in the recurrence rates in patients with PCNA values below or above 10% (p = 1.000, df = 1, [Fisher exact test]).
DISCUSSION
Factors such as pathological patterns, patient age, previous treatment (surgery or radiation therapy), extent of tumor removal, adjuvant postoperative radiation therapy, and cytogenetic abnormalies have been suggested to be related with the prognosis of patients with skull base chordomas and chondrosarcomas.
Pathological Patterns
Heffelfinger, et al., 23 have defined the variant chondroid of the chordoma and also found it to have a more benign clinical course, as also stated by others. 6 Using the criteria proposed by Heffelfinger, et al., for diagnosis of chordoma in our cases, we did not find significant difference between the survival and the RFS curves for patients with typical chordomas and chondroid chordomas; this finding lends support to the idea that the distinction of these subtypes has no practical meaning. Patients with chondrosarcomas have much better prognoses than those with chordomas when treated with surgery or proton-beam radiotherapy. 20, 22, 39 Analysis of our data corroborates this statement.
Patient Age
The age of the patient has been suggested to have an important role in the prognosis of skull base chordomas. 7, 13, 31 Chordomas in children behave very aggressively and have high levels of mitotic activity, hypercellularity, and pleomorphism; 13 some authors have suggested that the prognosis for patients younger than 40 years of age is significantly better than that for the older population. 21 The 5-and 10-year survival rates for the younger population were 75% and 63%, respectively, compared with 30% and 11% for the older population. 21 In a review of the literature on children and adolescents with chordomas, Borba, et al., 7 found that the prognosis is significantly worse for patients younger than 5 years of age because of the extremely diverse and malignant pathological appearance of these tumors in this age group; however, age was not shown to be a prognostic factor in the evolution of our patients considering the division by decade of life or trying to establish an age of cut.
Surgical Treatment
Treatment of patients with chordoma of the skull base is a challenge for neurosurgeons. Because of the origin of the tumor from the bone at the base of the skull, exceptionally complete resection can be achieved. Microscopic total removal of chordoma frequently is followed by the finding of residual tumor in the postoperative computer-ized tomography and MR images. The recurrence rate, even after radical resection, remains high. 32 The deep localization of chordomas at the middle of the skull base makes surgical access to these tumors difficult; nevertheless, many approaches lead to the clival from the superior, anterior or lateral view. The patterns of spread of the skull base chordoma preclude the use of a single surgical approach. Approaches to chordomas of the skull base should be based on the characteristics of growth in each case, and sometimes two or more skull base procedures may be necessary to achieve a radical removal. Extensive excision has an important role in the treatment of skull base chordoma; however, sometimes unacceptable procedure-related morbidity may occur. Currently, many authors consider that most cases of chordoma should be treated with resection. 1, [40] [41] [42] The average survival for patients with untreated chordoma is estimated to be 28 months after the onset of symptoms. 32 Survival after surgery or radiation therapy, or both, ranges from 3.6 to 6.6 years, and all tumors are seen to recur with time. 27, 36, 38 On average, recurrence is observed from 2 to 3 years after primary treatment, but sometimes the tumor recurs more than 10 years after initial treatment. Postoperative Functional Outcome. Preoperative, postoperative, and follow-up assessment of disability, as reflected by KPS scores, in patients with chordomas and chondrosarcomas allows surgeons to detect patients who have worsened due to surgical treatment and due to tumor regrowth or recurrence. Permanent postoperative functional deterioration and improvement assessed using the KPS, usually in 10 points, has been observed in 40% and 20% of patients, respectively, with chordomas and chondrosarcomas. 22 In our series there was no oscillation in the KPS score after surgery, but 7.5% of the patients with chordomas worsened due to tumor removal and none improved, and another 5.6% worsened during the first 6 months postoperatively due to tumor regrowth or recurrence.
Mortality Rate. The mortality rate for patients with chordomas varies according to the duration of the followup period (14-67% in a range of 1.9-5 years median follow up), 21, 22, 45 and the surgery-related mortality has been reported as 5%. 22 In our study, the postoperative mortality rate was 1.6% for all patients and 1.9% for those with chordomas. The global mortality rate during the followup period (median 38 months) was 17%, and patients in whom a previous surgery had been performed were at greater risk of death. No patient with chondrosarcoma died.
Survival and Recurrence Rates. Total or near-total tumor resection of craniocervical chordomas and chondrosarcomas ranges from 62 to 78.5%. 5, 21, 22, 31 The estimated overall survival rates for patients with chordomas are 13 to 51 and 18 to 35% at 5 and 10 years after resection, respectively. 21, 35 The frequency of recurrence of chordomas and chondrosarcomas ranges from 12 to 60% in a median follow-up period of 1.9 to 30 years. 22, 45 Overall 5-year RFS rates for patients in whom total or near-total resections and subtotal or partial resections are achieved range from 55 to 84% and 36 to 64%, respectively. 5, 21, 22 The estimated disease-free survival rates range from 33 to 76% at 5 years 21, 22 and to 24% at 10 years. 21 In patients with a history of surgery the survival rate is worse than in those without a history of surgery (RFS rates of 64% and 93% at 5 years, respectively). 22 In our series radical and subtotal resections (Ͼ 90%) were achieved in 77.8% of all patients. In addition, in patients with chordomas, radical or subtotal resection provided better RFS rates than in those in whom partial resection was attained (p Ͻ 0.005, three groups [Kruskal-Wallis nonparametric test]; p Ͻ 0.05 for radical/partial and p Ͻ 0.001 for subtotal/partial resection [Dunn multiple comparisons posttest]). Although there was no significant difference between survival rates in patients who underwent radical and subtotal resection, the small number and the different size of the samples tend to reduce the power of test, and a larger sample will be necessary for further comparisons. In our series, in chordoma patients who had not previously undergone surgery elsewhere, there was a better chance of achieving radical resection and better RFS rates than in those who had previously undergone surgery (67.6% and 32.5%, respectively, at 5 years). These data reinforce the contention that the extent of resection is correlated with lower risk of recurrence and that previous surgery is associated with a greater risk of recurrence. 6, 21, 22, 31 Complications. Gay, et al., 22 reported new cranial nerve deficits in 80% of the patients in their series, and the majority completely or partially resolved during the follow up. Cerebrospinal fluid leakage was observed in 30% of patients with chordomas and chondrosarcomas (10% experienced meningitis), and this complication was also correlated with permanent disability. Menezes, et al., 31 reported no CSF leakage or new cranial nerve palsies. In our series surgery-related complications were observed in 60.3% and neurological complications, mainly cranial nerve palsies, in 58.7%. Additional permanent and transient postoperative neurological deficits occurred in 28.6% and 22.2% of patients, respectively. On the other hand, 30% of the preoperative cranial nerve palsies improved after surgery. The best chance of postoperative deficit resolution was associated with sixth cranial nerve palsies, followed by seventh, third, and fifth cranial nerves palsies. Preoperative fourth, fifth (facial pain), and seventh cranial nerves palsies were shown to have the best chance of recovery after surgery. Nonneurological complications were related to the surgical approach or associated procedures. Despite a greater number of surgery-related complications in patients receiving radical resection, the proportions of patients with surgery-related complications that had radical and subtotal resection were not significantly different (p = 0.3739, df = 1, [Fisher exact test]).
Radiation Therapy
Conventional Radiation Therapy. Although chordomas were considered relatively resistant to conventional radiotherapy, this treatment has been used in patients with chordomas postoperatively. Conventional radiotherapy does not appear to increase survival rates, 2, 11, 12, 15, 19, 21, 36 but it has been shown to be associated with longer diseasefree survival in patients younger than 40 years of age. 21 The optimum dose of conventional radiation that should be administered after surgery is not well established, but higher doses (6000-7500 rads) are considered more effective than lower doses. Chordomas of the skull base able to demonstrate differences between lower and higher doses of radiation. 14, 15 Nevertheless, there is some agreement in the literature that if conventional radiotherapy is to be used, at least 5,000 rads should be administered. 28 In our series despite the small number of cases previously treated with conventional radiotherapy elsewhere, based on RFS curves, we did not find significant difference between these patients and those not treated with radiation therapy preoperatively in our institutions (p = 0.8051). Based on RFS curves patients who underwent conventional radiotherapy after surgery had the same prognosis as those who did not.
Heavy Particle Radiation Therapy. In patients with chordomas treated with stereotactic fractionated photon or proton-beam radiotherapy or combined proton-photon irradiation the 5-year actuarial tumor control rate ranges from 68 to 85%. 3, 4, 6, 10, 17, 25, 39 Local recurrences occur in 15 to 31% of the patients with a median time to local failures of 32 to 60 months. 4, 17, 43 Hug, et al., 25 reported that in all patients with tumor volumes smaller than 25 ml the tumor remained controlled compared with 56% of tumors with volumes greater than 25 ml. In our series, proton-beam radiotherapy was associated with significantly less recurrence than conventional radiotherapy (p Ͻ 0.05). In one study proton-beam radiotherapy was the cause of visual deficits in 4.4% and pituitary insufficiency in 13.2%. 4 Other complications include radiation-related osteonecrosis of the temporal bone and effects on the brainstem. 1 In our series these complications were observed in three patients (12%) with chordomas and one patient with chondrosarcoma. Characteristically, clinical and radiological signs of radiation-induced necrosis occurred later. Similar results have been observed when chordoma with charged particle irradiation (with helium), including radiation complications, 6 ,10 patients in whom extensive resection was achieved and patients with chondroid chordomas had better outcomes. 6, 10 Analysis of our data suggests that proton-beam radiotherapy or combined proton-photon radiotherapy is effective in controlling tumor growth and that the relation of the tumor with vital structures is the major factor of limitation in this treatment. Unfortunately, in all skull base chordomas, vital structures such as the brainstem and optic nerve are in direct relation with the tumor. The better results obtained using proton-beam compared with conventional radiotherapy in our cases can be explained by two potential reasons. First, the radiation doses used in proton-beam radiotherapy were higher than those used in conventional radiation therapy (proton-beam radiotherapy can be more conformal than conventional radiation therapy, due to the Bragg peak effect, and can deliver higher and safer doses). 10, 26 Second, despite even equivalent doses, the protons have an improved relative biological effectiveness over photons. 10, 26 Radiosurgery. The role of radiosurgery in the treatment of patients with skull base chordomas has been scarcely reported in the literature. Analysis of the available data on cases in which the gamma knife has been used as an adjunct to surgery in patients with chondromas and chondrosarcomas suggests that this modality can reduce or control the progression of the tumor, especially in patients with small-volume tumors (Ͻ 30 ml). 6, 10, 29, 34 Nevertheless, more data are necessary to form conclusions about the efficacy of gamma knife radiosurgery in patients with these lesions.
Cytogenetic Analysis. Cytogenetic abnormalities have been described in patients with cranial base tumors, and the presence of these abnormalities may be of diagnostic and prognostic value. 16, 18 Mitchell, et al., 33 found that typical and chondroid chordomas possess similar proportions of diploid and tetraploid populations of cell. Although they occasionally found aneuploidy in chondroid chordoma but not in typical chordoma, both demonstrated similar behavior. Buonamici, et al., 9 did not find chromosome anomalies in chordoma. Despite the small number of patients in whom cytogenetic analyses were performed in our series (three with diploid and four with aneuploid cell populations), the presence of aneuploid cell population seems not to interfere with the prognosis of patients, as reflected by the RFS curves (p = 0.05). Aneuploidy was observed in both typical and chondroid chordomas. In our series, abnormal karyotype was found in 50% of the analyzed cases, and it was more frequent in patients with chordomas (64.3%) than chondrosarcomas (25%). Despite no difference in the survival curves of patients with normal and abnormal karyotypes, the recurrence rate was higher in patients with abnormal karyotypes (p = 0.0042, df = 1 [Fisher exact test]).
Additional Studies and Survival. We were unable to find published reports on the role of evaluating steroids and PCNA in skull base chordomas. Assays for estrogen and progesterone receptors performed in seven patients with chordoma revealed low positivity for both (7.7%). Based on the results, these tests do not seem to be important for determining the prognosis of patients with chordoma. Despite the small number of examinations (12) , based on the RFS curves, we did not find an elevated PCNA index (Ͼ 10%) to be correlated with prognosis.
CONCLUSIONS
Chordomas of the skull base are rare tumors, the histopathological findings of which are many times not directly related to the outcome of the patients. Because of its rarity, few neurosurgeons become familiar with the surgical treatment of skull base chordoma and, alternatively, other modalities have been used for this with variable results. The development of the skull base surgery made possible the radical removal of chordomas. Nevertheless, because of the high morbidity rate and because of the absence of cure, doubts have arisen regarding the value of surgical procedures for treating patients with chordomas. The treatment of chordomas of the skull base remains controversial. In this study we found the following prognostic factors to influence the RFS: histological features (chordomas or chondrosarcomas), previous treatment (surgery and possibly conventional radiotherapy), extent of resection, adjuvant proton-beam radiotherapy, and possibly the karyotype. Analysis of our data also underscores the opinion that the best management of patients with chordomas of the craniocervical junction is to perform the most extensive resection possible and to undertake adjuvant proton-beam radiotherapy.
